Typhoid Vi Polysaccharide Vaccine
drugOn this page
Also known as Bacillus typhiSalmonella choleraesuis typhiSalmonella enterica ser. typhiSalmonella enterica serovar typhiSalmonella typhiSalmonella typhimuriumSalmonella typhosaTyphoid vaccineTyphoid vaccine antigensVaccinestyphoid
Summary
Typhoid Vi Polysaccharide Vaccine (CHEMBL2108822) is a phase-3 clinical-stage vaccine component; indicated across 2 conditions including hepatitis a virus infection and malaria.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Vaccine component
- Indications: 2 conditions
- Clinical trials: 11
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL2108822 |
| Name | Typhoid Vi Polysaccharide Vaccine |
| Type | Vaccine component |
| Max phase | 3 |
Also known as: Bacillus typhi, Salmonella choleraesuis typhi, Salmonella enterica ser. typhi, Salmonella enterica serovar typhi, Salmonella typhi, Salmonella typhimurium, Salmonella typhosa, Typhoid vaccine, Typhoid vaccine antigens, Typhoid vi polysaccharide vaccine, Vaccines, typhoid
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| hepatitis A virus infection | 3 | MONDO:0005790 | EFO:0007305 |
| malaria | 2 | MONDO:0005136 | EFO:0001068 |
Clinical trials
Total trials: 11.
Phase distribution
| Phase | Trials |
|---|---|
| EARLY_PHASE1 | 4 |
| Not specified | 3 |
| PHASE1 | 2 |
| PHASE4 | 1 |
| PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT03889158 | PHASE4 | TERMINATED | Effect of Age and Fitness on Vascular Function and Oxidative Stress During Acute Inflammation |
| NCT01466387 | PHASE3 | COMPLETED | A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults |
| NCT01099631 | PHASE1 | COMPLETED | IL-2 Expressing, Attenuated Salmonella Typhimurium in Unresectable Hepatic Spread |
| NCT02715635 | PHASE1 | COMPLETED | Influence of Dietary Nitrate on Vascular Dysfunction and Inflammation |
| NCT01582321 | EARLY_PHASE1 | COMPLETED | Investigation of the Influence of Gender on Cardiovascular Function |
| NCT02415387 | EARLY_PHASE1 | COMPLETED | Typhoid Vaccine in Testing Response to Immune Stress in Patients With Stage I-IIIA Breast Cancer |
| NCT03048929 | EARLY_PHASE1 | COMPLETED | Inflammation and Threat Sensitivity in PTSD |
| NCT03294564 | EARLY_PHASE1 | COMPLETED | Cognitive, Emotional, and Neural Responses to Acute Inflammation |
| NCT05870150 | Not specified | ACTIVE_NOT_RECRUITING | Challenge Non-Typhoidal Salmonella (CHANTS) Study |
| NCT02192008 | Not specified | COMPLETED | Investigating Enteric Fever - Salmonella Typhi and Paratyphi Challenge Study |
| NCT02628054 | Not specified | COMPLETED | Investigating the Effects of Typhoid Vaccine on Sleep in Healthy Volunteers |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: hepatitis A virus infection